ArticleCancer cell international2020
Identification of a m
Article in Cancer cell international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 48 citations in OpenAlex.
- Unveiling the epigenetic landscape: transforming renal cell carcinoma treatment.Clinical epigenetics · 2026Review
- METTL3: a multifunctional regulator in diseases.Molecular and cellular biochemistry · 2025Review
- The role of N6-methyladenosine (mPeerJ · 2025Review
- Methyltransferase-like 3 is a target for the diagnose and therapy of clear cell renal carcinoma.Frontiers in pharmacology · 2025Review
- Tumor Microenvironment in Clear Cell Renal Cell Carcinoma: A Comprehensive Analysis.Iranian journal of public health · 2024Article
- Nucleic acid and protein methylation modification in renal diseases.Acta pharmacologica Sinica · 2024Review
- Exploring the role of mFrontiers in oncology · 2024Review
- Detecting the Tumor Prognostic Factors From the YTH Domain Family Through Integrative Pan-Cancer Analysis.Cancer informatics · 2024Article
- Predicting response of immunotherapy and targeted therapy and prognosis characteristics for renal clear cell carcinoma based on m1A methylation regulators.Scientific reports · 2023Article
- Dysregulation and implications of N6-methyladenosine modification in renal cell carcinoma.Current urology · 2023Article
- Review
- The lncRNA epigenetics: The significance of m6A and m5C lncRNA modifications in cancer.Frontiers in oncology · 2023Review
- The emerging roles and mechanism of N6-methyladenosine (mFrontiers in pharmacology · 2023Review
- The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma.Journal of translational medicine · 2022Article
- mExperimental hematology & oncology · 2022Review
- Functions, mechanisms, and therapeutic implications of METTL14 in human cancer.Journal of hematology & oncology · 2022Review
- OAS3 is a Co-Immune Biomarker Associated With Tumour Microenvironment, Disease Staging, Prognosis, and Treatment Response in Multiple Cancer Types.Frontiers in cell and developmental biology · 2022Article
- Construction of a Prognostic Model for KIRC and Identification of Drugs Sensitive to Therapies - A Comprehensive Biological Analysis Based on m6A-Related LncRNAs.Frontiers in oncology · 2022Article
- Comprehensive Analysis of N6-Methyladenosine (mCanadian journal of gastroenterology & hepatology · 2022Article
- Effect of the m6ARNA gene on the prognosis of thyroid cancer, immune infiltration, and promising immunotherapy.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe mortality rate of clear cell renal cell carcinoma (ccRCC) remains high. The aim of this study was to identify novel prognostic biomarkers by using m
methodsThe gene expression data of 16 m
resultsFive m
conclusionsm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.